ERJ Podcast: GOLD 2023
abril 30, 2023
Chief Editor James Chalmers interviews Alvar Agusti (Hospital Clinic, Barcelona, Spain)about the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Listen it here.
Chief Editor James Chalmers interviews Alvar Agusti (Hospital Clinic, Barcelona, Spain)about the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Listen it here.
«Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision…»
El pasado mes de febrero la UB celebró en su sala Paraninfo La “Barcelona Boston Lung Conference”, un foro anual de debate científico al más alto nivel sobre diversos aspectos de las enfermedades respiratorias, con un elenco de ponentes del máximo nivel internacional.
Àlvar Agustí ha participado en este evento como miembro del comité científico de la reunión, resaltando la importancia de “pasar de una medicina reactiva a una medicina predictiva…»
«Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision…»
Approximately 25% and 65% of patients hospitalized for an ECOPD die within 1 and 5 years, respectively.
The European Respiratory Journal is voluntarily reviewed. We are most grateful for the hard work and dedication of all those who reviewed articles for the ERJ in 2022.
Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19.
«Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision…»
Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. (…)